Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in interests in Ordinary shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share allocations rather than a financial performance report.
Material Changes
On March 31, 2010, Non-Executive Directors were provisionally allocated awards under share allocation arrangements for the service period of January 1, 2010, to March 31, 2010. The allocation prices were set at £12.67 per Ordinary share and $38.29 per ADS. These allocations were communicated to the Company and the Directors on April 1, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Date: Awards were provisionally allocated on March 31, 2010, and notified on April 1, 2010.
- Share Prices: Allocations were based on £12.67 per Ordinary share and $38.29 per ADS.
- Directors Involved: Awards were distributed to Sir Christopher Gent, Prof. Sir Roy Anderson, Dr. Stephanie Burns, Mr. Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Mr. James Murdoch, Dr. Daniel Podolsky, Mr. Tom de Swaan, and Sir Robert Wilson.
- Specific Allocations: Sir Crispin Davis received the highest number of Ordinary shares (3,058.41), while Dr. Stephanie Burns received the lowest (399.73).